Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERLINK-1 monalizumab plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck after immune checkpoint inhibitor therapy
NL-OMON56351Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Monalizumab + cetuximab with Placebo + cetuximab (2 arms). Primary endpoint: Overall survival in HPV-unrelated participants. Started Feb 2021; status: active, not recruiting.
02
Drugs
monalizumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON56351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56351.